share_log

ALLARITY THERAPEUTICS INC | UPLOAD: Others

ALLARITY THERAPEUTICS INC | UPLOAD: Others

Allarity Therapeutics | UPLOAD:其他
美股SEC公告 ·  2024/02/28 01:39

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. has completed an amendment to its Preliminary Proxy Statement on Schedule 14A, which was initially filed on February 23, 2024. The United States Securities and Exchange Commission (SEC), through the Division of Corporation Finance Office of Life Sciences, has concluded its review of the amended filing. In a letter dated February 27, 2024, addressed to Thomas Jensen, CEO of Allarity Therapeutics, the SEC issued a reminder to the company and its management regarding their responsibility for the accuracy and adequacy of their disclosures. This communication confirms that the SEC has no further comments on the amendment at this time.
Allarity Therapeutics, Inc. has completed an amendment to its Preliminary Proxy Statement on Schedule 14A, which was initially filed on February 23, 2024. The United States Securities and Exchange Commission (SEC), through the Division of Corporation Finance Office of Life Sciences, has concluded its review of the amended filing. In a letter dated February 27, 2024, addressed to Thomas Jensen, CEO of Allarity Therapeutics, the SEC issued a reminder to the company and its management regarding their responsibility for the accuracy and adequacy of their disclosures. This communication confirms that the SEC has no further comments on the amendment at this time.
Alarity Therapeutics, Inc.已經完成了對附表14A的初步委託書的修訂,該聲明最初於2024年2月23日提交。美國證券交易委員會(SEC)已通過公司財務部生命科學辦公室完成了對修訂申請的審查。在2024年2月27日致Allarity Therapeutics首席執行官托馬斯·詹森的一封信中,美國證券交易委員會提醒該公司及其管理層對披露的準確性和充分性負責。該來文證實,美國證券交易委員會目前對該修正案沒有進一步的評論。
Alarity Therapeutics, Inc.已經完成了對附表14A的初步委託書的修訂,該聲明最初於2024年2月23日提交。美國證券交易委員會(SEC)已通過公司財務部生命科學辦公室完成了對修訂申請的審查。在2024年2月27日致Allarity Therapeutics首席執行官托馬斯·詹森的一封信中,美國證券交易委員會提醒該公司及其管理層對披露的準確性和充分性負責。該來文證實,美國證券交易委員會目前對該修正案沒有進一步的評論。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息